The Combination of Conventional Chemotherapy with New Targeted Therapy in Hematologic Malignancies: The Safety and Efficiency of Low- Dose Cytarabine Supports its Combination with New Therapeutic Agents in Early Clinical Trials

Publisher： Bentham Science Publishers

E-ISSN： 1875-6301|5|4|243-255

ISSN： 1573-3947

Source： Current Cancer Therapy Reviews, Vol.5, Iss.4, 2009-11, pp. : 243-255

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current status of molecular targeted therapy for hematologic malignancies: introduction

By Ueda Takanori  

International Journal of Clinical Oncology, Vol. 19, Iss. 1, 2014-02 ,pp. : 1-2

Springer Publishing Company

Access to resources Recommend Favorite

Combination Therapy with Arsenic Trioxide for Hematological Malignancies

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 10, Iss. 6, 2010-07 ,pp. : 504-510

Bentham Science Publishers

Access to resources Recommend Favorite

Synthesis of New Antibacterial Cubane-based Nanocomposite and its Application in Combination Cancer Therapy

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 17, Iss. 14, 2018-02 ,pp. : 1898-1914

Bentham Science Publishers

Access to resources Recommend Favorite

Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies

By          

International Journal of Oncology, Vol. 45, Iss. 4, 2014-01 ,pp. : 1742-1748

Spandidos Publications

Access to resources Recommend Favorite

Development of Farnesyltransferase Inhibitors for Clinical Cancer Therapy: Focus on Hematologic Malignancies

By Karp Judith   Lancet Jeffrey  

Cancer Investigation, Vol. 25, Iss. 6, 2007-09 ,pp. : 484-494

Informa Healthcare

Access to resources Recommend Favorite